Mixed regimen for treating infertility

Insufficient oocyte count and OHSS risks were addressed by using an individualized AMH and weight-based dosing regimen in patients over 35 years of age, combined with a mixed protocol of α2,3- and α2,6-sialized rFSH and hMG. High problems improve ovarian stimulation effect and safety.

CN118922201APending Publication Date: 2024-11-08FERRING BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280094136.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-04-01
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Among the existing assisted reproductive technologies, the individualization of ovarian stimulation programs for patients over 35 years old has not been effectively resolved, resulting in insufficient oocyte count and pregnancy rate and a high risk of excessive ovarian response.

Method used

Using an individualized dosing regimen based on anti-Mullerian hormone (AMH) and body weight, using recombinant human follicle-stimulating hormone (rFSH) and gametopromoting hormone (hMG) that includes α2,3- and α2,6-sialylation Mix the protocol to adjust the drug dose to optimize ovarian stimulation and reduce the risk of overreaction.

Benefits of technology

Significantly increased the number of high-quality blastocysts obtained by patients aged 35-40 on embryo culture on days 5-6, reduced the incidence of ovarian hyperstimulation syndrome (OHSS) at any level, and reduced dose adjustments to gamete-promoting hormones need.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005057843290000301
    Figure BDA0005057843290000301
  • Figure BDA0005057843290000311
    Figure BDA0005057843290000311
  • Figure BDA0005057843290000321
    Figure BDA0005057843290000321
Patent Text Reader

Abstract

Methods, uses, and products are described for use in the treatment of infertility in patients of > = 35 years old comprising a recombinant human follicle stimulating hormone (rFSH) comprising alpha 2, 3-and alpha 2, 6-sialylation and a gametogenic maturation hormone (human menopausal gonadotropin or hMG).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to pharmaceutical products and methods for treating infertility. Background Art

[0002] Assisted reproductive technologies (ART) such as in vitro fertilization (IVF) are well known. ART generally requires a controlled ovarian stimulation (COS) step in which a group of follicles are stimulated to full maturity. Standard COS protocols involve the administration of gonadotropins, such as gametogenic hormones (e.g., human menopausal gonadotropin (hMG) and follicle-stimulating hormone (FSH)), alone or in combination with luteinizing hormone (LH) activity, to stimulate the development of multiple follicles. Typically, COS requires the administration of GnRH analogs (GnRH agonists) or GnRH antagonists before and / or during stimulation to prevent a premature surge in LH, which could induce ovulation prior to planned oocyte retrieval. The goal of COS is generally to stimulate the maturation of multiple follicles so that, when ovulation is triggered, multiple oocytes can be retrieved for fertilization. Generally, the best oocytes are selected for implantation, while others may be cryopreserved for future use.

[0003] In cases of excessive ovarian response, COS may be associated with a risk of ovarian hyperstimulation syndrome (OHSS), which may lead to cancellation of the COS cycle and, in severe cases, may be life-threatening. The ability to predict a woman's potential for ovarian response to COS may allow for the development of a personalized or individualized COS regimen. For example, such an individualized regimen could reduce the risk of OHSS in women predicted to have an excessive ovarian response to COS and prevent cancellation of COS cycles. Levels of anti-Müllerian hormone (AMH) are directly correlated with the ovarian response to gonadotropins during COS. Therefore, high levels of AMH are a good predictor of excessive ovarian response and an indicator of OHSS risk, whereas low levels of AMH predict a poor ovarian response to COS. Other predictors of ovarian response include age, body mass index (BMI), FSH, and antral follicle count (AFC).

[0004] In humans, FSH and LH work together to stimulate follicle formation and ovulation. Therefore, these gonadotropins are usually used in COS to increase the number of oocytes produced in IVF. This FSH-LH combination concept has led to the so-called "mixed scheme", i.e., the use of hMG and FSH for combined treatment for ovarian stimulation is widely used. In fact, the COS scheme using hMG (the source of FSH and LH activity) and FSH is usually used to try to obtain oocytes and embryos with better quality, thereby obtaining a higher pregnancy rate compared to the use of recombinant FSH alone. The determination of the stimulation scheme and FSH dosage is usually established by a doctor based on a variety of parameters, which can include various combinations of patient age, weight and ovarian reserve curves (AMH, AFC, BMI, etc.). However, to date, for patients over 35 years old, the individualization of the mixed scheme of follitropin δ (recombinant FSH expressed in human cell lines) and HP-hMG has not yet been achieved.

[0005] Therefore, there is a need for improved assisted reproductive technology methods, especially improved mixed hMG and FSH regimens for patients over 35 years of age. Summary of the invention

[0006] In the exploratory studies described below, the applicants demonstrated the effectiveness of a combination regimen of gametogenic maturation hormone (human menopausal gonadotropin (hMG)) and recombinant human follicle-stimulating hormone (rFSH) (e.g., follitropin delta) personalized based on AMH and weight in the treatment of infertility in patients ≥35 years of age.

[0007] The results of the study showed that the number of good-quality, usable blastocysts obtained on embryo culture day 5 or 6 could be statistically significantly increased using this combined regimen (without compromising safety) compared with cycles using follitropin delta as monotherapy. The subgroups of patients aged 35 to 36 years and 37 to 40 years seemed to benefit most from the use of this combined regimen. For example, the mean (corrected) number of good-quality blastocysts on days 5 to 6 after fertilization was 4.03 ± 0.72 and 4.24 ± 0.62 in the 35.0-36.9 and 37.0-40.0 age groups, respectively, compared with 2.0 ± 2.2 in all age groups using follitropin delta as monotherapy. The incidence of OHSS of any grade was 9.3% (7.4% in the elderly group, 35.0-36.9 age group, and 37.0-40.0 age group) compared with 2.6% in the corresponding groups using follitropin delta as monotherapy. No moderate or severe cases of OHSS were observed in this study, whereas OHSS cases were observed in 1.4% of patients using follitropin delta as monotherapy. Therefore, the dosing regimen disclosed herein achieved the desired goal. For the 35.0-36.9 and 37.0-40.0 age groups, the percentage of patients who did not require a dose adjustment of gametogenic maturation hormone (HP-hMG) was 70.83% and 54.84%, respectively. Since this study was exploratory and adjustments to the drug regimen were expected, it is noteworthy that this percentage of these patients did not require a change in the HP-hMG dose.

[0008] According to some aspects, products are provided, which include gametogenic hormone (human menopausal gonadotropin (hMG), such as highly purified hMG (HP-hMG)) and recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation; wherein the product is used to treat infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the product will be administered as follows: the recombinant human FSH including α2,3- and α2,6-sialylation is at a dose of or equivalent to 11-13 μg (e.g., 12 μg) per day, and the gametogenic hormone is at a dose of or equivalent to 37.5 IU to 225 IU HP-hMG per day. The dose of hMG can be a gametogenic hormone at a dose of or equivalent to 75 IU to 225 IU HP-hMG per day.

[0009] The use may include the step of determining the patient's serum AMH level, and administering a dose of recombinant human FSH including α2,3- and α2,6-sialylated FSH and a dose of gamete maturation hormone to a patient with a serum AMH level <15 pmol / L. The use may further include determining the patient's serum estradiol (E 2 ) level (e.g., monitoring the response to stimulation and subsequently adjusting the dose of gametogenin, or helping to select a triggering drug).

[0010] In some aspects, the product can be administered from day 1 of stimulation to at least day 5, 6, or 7 of stimulation. From day 6, 7, or 8 of stimulation, the product can be administered at a daily dose of a gamete maturation hormone (maintaining the rFSH dose at the (initial) day 1 dose), the daily dose of the gamete maturation hormone being based on the patient's serum estradiol (E 2 ) levels. From the 6th, 7th or 8th day of stimulation, (i) on the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level> 3000 pmol / L, the daily dose of gametogenic hormone can be reduced by up to 75 IU (relative to the starting dose) (e.g., by 37.5 IU, by 75 IU, or by any amount between 37.5 IU and 75 IU); or (ii) on day 5, 6, or 7 of stimulation, estradiol (E 2 ) level >3000 pmol / L, the daily dose of gametogenic hormone can be reduced to zero. Starting from the 6th, 7th or 8th day of stimulation, (i) on the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level of 750-999 pmol / L, the daily dose of gametogenic hormone may be increased (relative to the starting dose) by up to 150 IU (e.g., by 75 IU, by 150 IU, or by any amount between 75 IU and 150 IU), or (ii) on day 5, 6, or 7 of stimulation with estradiol (E 2 In patients with estradiol levels < 750 pmol / L, the daily dose of gametogenic hormone was increased to 225 IU starting on day 6, 7, or 8 of stimulation. 2 In patients with GABAergic levels between 1000 and 3000 pmol / L, the daily dose of gametogenetic hormone (at the starting dose) can be maintained.

[0011] The use may include the additional step of triggering ovulation by administering hCG to a patient who, after stimulation, has ≥ 3 follicles each ≥ 17 mm in diameter and estradiol (E 2) level <10,000 pmol / L; or GnRH agonists are administered to patients who have ≥3 follicles with a diameter of ≥17 mm each and estradiol (E 2 ) level between 10,000 pmol / L and 15,000 pmol / L; or administration of a GnRH agonist to a patient who has ≥20 follicles and each follicle is ≥12 mm in diameter after stimulation and / or estradiol (E 2 ) levels ≥ 15,000 pmol / mL or ≥ 20,000 pmol / mL. The dose of hCG to be administered to the patient may be 5,000 IU to 10,000 IU.

[0012] Use may include the additional step of administering a GnRH antagonist starting on day 6 of stimulation.

[0013] Use may further include one or more or all of the following: extracting (e.g., harvesting) one or more oocytes; fertilizing the one or more oocytes (e.g., artificial insemination); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) blastocysts.

[0014] In some aspects, gametogenic hormone and rFSH comprising α2,3- and α2,6-sialylation are administered separately, for example, rFSH comprising α2,3- and α2,6-sialylation is used for administration in the morning, and gametogenic hormone is used for administration in the afternoon or evening. In some aspects, gametogenic hormone and rFSH comprising α2,3- and α2,6-sialylation are administered together.

[0015] In some aspects, gamete maturation hormone is highly purified gamete maturation hormone (HP-hMG). In some aspects, rFSH is wherein 50% to 95% of total sialylation is α2,3-sialylation and wherein 5%-50% of total sialylation is α2,6-sialylated rFSH. In some aspects, rFSH is wherein 80% to 90% of total sialylation is α2,3-sialylation and wherein 10%-20% of total sialylation is α2,6-sialylated rFSH (e.g., follitropin δ, available from Ferring Pharmaceuticals (Ferring BV)).

[0016] In some aspects, the initial daily dose of gametocyte maturation hormone (hMG) is: 75 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is <12 μg; 150 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is 12 μg and the patient weighs <100 kg; and 225 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is 12 μg and the patient weighs ≥100 kg.

[0017] Use may include an additional step of assessing follicular growth by ultrasound examination, for example on days 9, 10, 11, 12, 13, 14, etc. of stimulation.

[0018] According to some aspects, products are provided, which contain gamete maturation hormone and recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation; wherein the product is used in the treatment of infertility in patients ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) with serum AMH levels ≥15 pmol / L (e.g., 15-35 pmol / L) before treatment / stimulation; and wherein the product will be administered as follows: the dose of recombinant human FSH including α2,3- and α2,6-sialylation is or is equivalent to 0.09-0.19 μg per kg of patient body weight per day, and the dose of gamete maturation hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day. The dose of hMG can be a dose of gamete maturation hormone at or is equivalent to 75 IU to 225 IU HP-hMG per day.

[0019] The use may include the step of determining the patient's serum AMH level, and administering a dose of recombinant human FSH including α2,3- and α2,6-sialylated FSH and a dose of gamete maturation hormone to a patient with a serum AMH level ≥ 15 pmol / L (e.g., 15-35 pmol / L). The use may further include determining the patient's serum estradiol (E 2 ) level (e.g., monitoring the response to stimulation and subsequently adjusting the dose of gametogenin, or helping to select a triggering drug).

[0020] In some aspects, the product can be administered from day 1 of stimulation to at least day 5, 6, or 7 of stimulation. From day 6, 7, or 8 of stimulation, the product can be administered at a daily dose of a gamete maturation hormone (maintaining the rFSH dose at the (initial) day 1 dose), the daily dose of the gamete maturation hormone being based on the patient's serum estradiol (E 2) levels. From the 6th, 7th or 8th day of stimulation, (i) on the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level> 3000 pmol / L, the daily dose of gametogenic hormone can be reduced by up to 75 IU (relative to the starting dose) (e.g., by 37.5 IU, by 75 IU, or by any amount between 37.5 IU and 75 IU); or (ii) on day 5, 6, or 7 of stimulation, estradiol (E 2 ) level >3000 pmol / L, the daily dose of gametogenic hormone can be reduced to zero. Starting from the 6th, 7th or 8th day of stimulation, (i) on the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level of 750-999 pmol / L, the daily dose of gametogenic hormone may be increased (relative to the starting dose) by up to 150 IU (e.g., by 75 IU, by 150 IU, or by any amount between 75 IU and 150 IU), or (ii) on day 5, 6, or 7 of stimulation with estradiol (E 2 In patients with estradiol levels < 750 pmol / L, the daily dose of gametogenic hormone was increased to 225 IU starting on day 6, 7, or 8 of stimulation. 2 In patients with GABAergic levels between 1000 and 3000 pmol / L, the daily dose of gametogenetic hormone (at the starting dose) can be maintained.

[0021] The use may include the additional step of triggering ovulation by administering hCG to a patient who, after stimulation, has ≥ 3 follicles each ≥ 17 mm in diameter and estradiol (E 2 ) level <10,000 pmol / L; or GnRH agonists are administered to patients who have ≥3 follicles with a diameter of ≥17 mm each and estradiol (E 2 ) level between 10,000 pmol / L and 15,000 pmol / L; or: administration of a GnRH agonist to a patient who has ≥20 follicles with a diameter of ≥12 mm and / or estradiol (E 2 ) levels ≥ 15,000 pmol / mL or ≥ 20,000 pmol / mL. The dose of hCG to be administered to the patient may be 5,000 IU to 10,000 IU.

[0022] Use may include the additional step of administering a GnRH antagonist starting on day 6 of stimulation.

[0023] Use may further include one or more or all of the following: extracting (e.g., harvesting) one or more oocytes; fertilizing the one or more oocytes (e.g., artificial insemination); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) blastocysts.

[0024] In some aspects, gametogenic hormone and rFSH comprising α2,3- and α2,6-sialylation are administered separately, for example, rFSH comprising α2,3- and α2,6-sialylation is used for administration in the morning, and gametogenic hormone is used for administration in the afternoon or evening. In some aspects, gametogenic hormone and rFSH comprising α2,3- and α2,6-sialylation are administered together.

[0025] In some aspects, gamete maturation hormone is highly purified gamete maturation hormone (HP-hMG). In some aspects, rFSH is wherein 50% to 95% of total sialylation is α2,3-sialylation and wherein 5%-50% of total sialylation is α2,6-sialylated rFSH. In some aspects, rFSH is wherein 80% to 90% of total sialylation is α2,3-sialylation and wherein 10%-20% of total sialylation is α2,6-sialylated rFSH (e.g., follitropin δ, available from Ferring Pharmaceuticals (Ferring BV)).

[0026] In some aspects, the initial daily dose of gametocyte maturation hormone (hMG) is: 75 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is <12 μg; 150 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is 12 μg and the patient weighs <100 kg; and 225 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is 12 μg and the patient weighs ≥100 kg.

[0027] Use may include an additional step of assessing follicular growth by ultrasound examination, for example on days 9, 10, 11, 12, 13, 14, etc. of stimulation.

[0028] According to some aspects, a method for treating infertility in a patient aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) and having a serum AMH level <15 pmol / L before treatment is provided, the method comprising: identifying a patient aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) and having a serum AMH level <15 pmol / L before treatment; and administering to the patient human menopausal gonadotropin (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated, wherein the rFSH is administered at a dose of 11-13 μg (e.g., 12 μg) rFSH per day or a dose equivalent thereto, and the hMG is administered at a dose of 37.5 IU to 225 IU highly purified hMH (HP-hMG) per day or a dose equivalent thereto. The dose of hMG may be a gamete maturation promoting hormone at a dose of or equivalent to 75 IU to 225 IU HP-hMG per day.

[0029] According to some aspects, a method for treating infertility in a patient ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) and having a serum AMH level of <15 pmol / L before treatment is provided, the method comprising: identifying a patient ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) and having a serum AMH level of ≥15 pmol / L (e.g., 15-35 pmol / L) before treatment; and administering to the patient human menopausal gonadotropin (hMG) and recombinant human follicle-stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated, wherein the rFSH is administered at a dose of 0.09-0.19 μg of rFSH per kg of patient body weight per day, or a dose equivalent thereto, and the hMG is administered at a dose of 37.5 IU to 225 IU of highly purified hMG (HP-hMG) per day, or a dose equivalent thereto. The dose of hMG may be a dose of gametogen at or equivalent to 75 IU to 225 IU HP-hMG per day.

[0030] According to some aspects, a pharmaceutical composition comprising gametogenic hormone (human menopausal gonadotropin or hMG) is provided for use in treating infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH levels before treatment / stimulation are <15 pmol / L; wherein the pharmaceutical composition is to be administered as follows: the dose of gametogenic hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day, and the dose of recombinant human FSH (rFSH) including α2,3- and α2,6-sialylated is or is equivalent to 11-13 μg (e.g., 12 μg) per day.

[0031] According to some aspects, a pharmaceutical composition comprising α2,3- and α2,6-sialylated recombinant human follicle-stimulating hormone (rFSH) is provided for use in treating infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the pharmaceutical composition is to be administered as follows: a dose of α2,3- and α2,6-sialylated recombinant human FSH is or is equivalent to 11-13 μg (e.g., 12 μg) per day, and a dose of gametogenic maturation hormone (human menopausal gonadotropin or hMG) is or is equivalent to 37.5 IU to 225 IU HP-hMG per day.

[0032] According to some aspects, a pharmaceutical composition comprising gametogenic hormone (human menopausal gonadotropin or hMG) is provided for use in treating infertility in patients ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) whose serum AMH level before treatment / stimulation is ≥15 pmol / L (e.g., 15-35 pmol / L); wherein the pharmaceutical composition is to be administered as follows: the dose of gametogenic hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day, and the dose of recombinant human FSH (rFSH) including α2,3- and α2,6-sialylated is or is equivalent to 0.09-0.19 μg per kg of patient body weight per day.

[0033] According to some aspects, a pharmaceutical composition comprising α2,3- and α2,6-sialylated recombinant human follicle-stimulating hormone (rFSH) is provided for use in treating infertility in patients ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) whose serum AMH level before treatment / stimulation is ≥15 pmol / L (e.g., 15-35 pmol / L); wherein the pharmaceutical composition is administered as follows: a dose of α2,3- and α2,6-sialylated recombinant human FSH is or is equivalent to 0.09-0.19 μg per kg of patient body weight per day, and a dose of gametogenic maturation hormone (human menopausal gonadotropin or hMG) is or is equivalent to 37.5 IU to 225 IU HP-hMG per day. DETAILED DESCRIPTION

[0034] Applicants have demonstrated the effectiveness of a combination regimen of gametogenetic hormone (hMG) and recombinant human follicle-stimulating hormone (rFSH) (e.g., follitropin delta), personalized based on AMH and weight, in treating infertility in patients ≥35 years of age.

[0035] The results of the study showed that the number of good-quality, usable blastocysts obtained on embryo culture day 5 or 6 could be statistically significantly increased using this combined regimen (without compromising safety) compared with cycles using follitropin delta as monotherapy. The subgroups of patients aged 35 to 36 years and 37 to 40 years seemed to benefit most from the use of this combined regimen. For example, the mean (corrected) number of good-quality blastocysts on days 5 to 6 after fertilization was 4.03 ± 0.72 and 4.24 ± 0.62 in the 35.0-36.9 and 37.0-40.0 age groups, respectively, compared with 2.0 ± 2.2 in all age groups using follitropin delta as monotherapy. The incidence of OHSS of any grade was 9.3% (7.4% in the elderly group, 35.0-36.9 age group, and 37.0-40.0 age group) compared with 2.6% in the corresponding groups using follitropin delta as monotherapy. No moderate or severe cases of OHSS were observed in this study, whereas OHSS cases were observed in 1.4% of patients using follitropin delta as monotherapy. Therefore, the dosing regimen disclosed herein achieved the desired goal. For the 35.0-36.9 and 37.0-40.0 age groups, the percentage of patients who did not require a dose adjustment of gametogenic maturation hormone (HP-hMG) was 70.83% and 54.84%, respectively. Since this study was exploratory and adjustments to the drug regimen were expected, it is noteworthy that this percentage of these patients did not require a change in the HP-hMG dose.

[0036] Therefore, provided herein are methods for constructing an individualized treatment and dosing regimen for treating infertility in patients ≥ 35 years of age.

[0037] definition

[0038] Unless otherwise defined, the technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art of assisted reproductive technology to which the present invention belongs. Reference is made herein to various methods known to those of ordinary skill in the art. Any suitable materials and / or methods known to those of ordinary skill in the art can be used to implement the present invention, according to the guidance provided herein. However, specific materials and methods are described. Unless otherwise stated, the materials, reagents, etc. referenced in the following description and examples can be obtained from commercial sources.

[0039] It should be understood that any definitions and terms defined herein are intended to have the same meaning and intent in any aspects and embodiments of the present invention unless expressly stated otherwise.

[0040] As used herein, the singular forms "a," "an," and "the" refer to both the singular and the plural, unless explicitly stated to refer to the singular only.

[0041] As used herein, the term "about" means that as will be understood by one of ordinary skill in the art, depending on the context in which a number or range is used, the number or range so modified is not limited to the exact number or range shown, but encompasses ranges around the stated number or range. Unless otherwise apparent from the context or custom in the art, "about" means up to plus or minus 10% of the particular term.

[0042] As used herein, "ongoing pregnancy" refers to a pregnancy with a viable fetus and a detectable fetal heartbeat at 10-11 weeks of gestation, such as 8-9 weeks after blastocyst / embryo transfer.

[0043] As used herein, "clinical pregnancy" refers to pregnancy and detectable fetal heartbeat at 5-6 weeks of gestation, such as 3-4 weeks after blastocyst / embryo transfer.

[0044] The terms "patient" and "subject," and "female" and "woman" are used interchangeably herein.

[0045] The term "treatment of infertility" includes treatment of infertility in subjects with tubal or unexplained infertility (including treatment of infertility in subjects with endometriosis (e.g., stage I or stage II endometriosis)), and / or infertility in subjects whose partners have male factor infertility. The product may be used to treat infertility (and / or for controlled ovarian stimulation) in subjects with endometriosis (e.g., in subjects with stage I or stage II endometriosis), as defined by the American Society for Reproductive Medicine (ASRM) classification system for various stages of endometriosis (stage IV is the most severe; stage I is the least severe) [American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67, 817 821].

[0046] Serum concentrations of anti-Mullerian hormone (AMH) are now established as a reliable marker of ovarian reserve. Decreased levels of AMH are associated with reduced ovarian response to gonadotropins during COS. In addition, high levels of AMH are a good predictor of excessive ovarian response and an indicator of OHSS risk. According to the present disclosure, for the first (and in some cases subsequent) treatment cycle, an individualized daily dose of recombinant human follicle-stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated is determined based on the woman's serum AMH concentration and (in certain embodiments) her weight. The dose of recombinant human follicle-stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated is based on the most recent (i.e., within the last 12 months) e.g., by The AMH that is measured and determined by AMH Plus immunoassay (Roche) or similar assays (such as ACCESS AMH Advanced from Beckman Coulter or UMIPULSE G AMH from Fujirebio) is measured. Additionally or alternatively, the serum concentration of anti-mullerian hormone (AMH) in the patient can be determined using the Beckmann-Coulter Gen 2 assay described in Arce et al., Fertility and Sterility [fertility and infertility] 99: 1644-53 (2013), or can be the equivalent AMH level assessed by different methods.

[0047] Subjects may have a BMI > 15 and a BMI < 40 kg / m 2 , such as BMI>17.5 and BMI<38kg / m 2 , such as BMI>18 and BMI<25kg / m 2 , for example, BMI>20 and BMI<25kg / m 2 Therefore, the products or methods described herein can be used to treat BMI>15 and BMI<40 kg / m 2 Subjects with BMI>17.5 and BMI<38 kg / m 2 Subjects with BMI>18 and BMI<25kg / m 2 Subjects with BMI>20 and BMI<25kg / m 2 Thus, the products or methods described herein can be used to treat infertility in subjects with a BMI>17.5 and a BMI<32 kg / m 2 BMI can be measured by methods well known in the art to identify patients for treatment.

[0048] The term "follicle" herein means an ovarian follicle, which is a fluid-filled sac that contains an immature egg or oocyte.

[0049] Blastocysts are formed in the early development of humans (or other mammals). In humans, blastocyst formation begins about 5 days after fertilization. The blastocysts used in IVF generally involve extracting (harvesting) multiple oocytes derived from a controlled ovarian stimulation cycle from women; fertilizing one or more oocytes (artificial insemination) and culturing the fertilized eggs (oocytes) for five days to form blastocysts (i.e., allowing the fertilized oocytes to develop to the blastocyst stage); and implanting the blastocysts into the uterus. Embryos are formed in the early development of humans (or other mammals). The embryos used in IVF generally involve extracting (harvesting) multiple oocytes derived from a controlled ovarian stimulation cycle from women; fertilizing one or more oocytes (artificial insemination) and culturing the fertilized eggs (oocytes) for, for example, 3 days to form embryos (i.e., allowing the fertilized oocytes to develop to the embryonic stage); and implanting the embryos into the uterus.

[0050] As used herein, the term "gametogenic hormone" includes human menopausal gonadotropin (hMG). As used herein, the term "highly purified gametogenic hormone" (HP-hMG) includes the HP-hMG available from Ferring Pharmaceuticals under the trademark HP-hMG comprising follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) driven luteinizing hormone (LH) activity. In some examples, the hMG is HP-hMG comprising follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) driven luteinizing hormone (LH) activity (e.g. ).

[0051] As used herein, the term "GnRH agonist" includes gonadotropin-releasing hormone (GnRH) agonists, such as buserelin (e.g., ), leuprolide (e.g., leuprolide acetate, e.g., ), nafarelin (e.g. ) and triptorelin (e.g. ).

[0052] As used herein, the term "GnRH antagonist" includes gonadotropin-releasing hormone (GnRH) antagonists, such as ganirelix acetate (e.g., ) and cetrorelix acetate (e.g. ), which blocks the action of GnRH by competitively blocking GnRH receptors on pituitary gonadotropins, thereby preventing the production / release of gonadotropins and premature ovulation (release of the egg).

[0053] According to all aspects described herein, the recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation may be a recombinant FSH derived from a human cell line, as described in more detail below. In all aspects, the recombinant FSH comprising α2,3- and α2,6-sialylation may be a recombinant FSH obtained under the trademark (Follitropin delta) is sold by Ferring Pharmaceuticals. In all aspects, the recombinant FSH can be administered by injection, for example subcutaneously.

[0054] As used herein, "the first day of treatment", also referred to as "the first day of stimulation", refers to the first day of administering a dose of gamete maturation hormone and recombinant human FSH including α2,3- and α2,6-sialylation to the patient. The first day of treatment (stimulation) may occur on the 1st, 2nd or 3rd day of the patient's menstrual cycle, such as the 2nd or 3rd day. In other words, the first day of treatment (stimulation) may be one, two or three days after the patient begins menstrual bleeding, such as two or three days, which is consistent with the usage of the term in the clinical practice of GnRH antagonist or GnRH agonist regimens. The term "treatment period" refers to one or several days of administering gamete maturation hormone and recombinant human FSH including α2,3- and α2,6-sialylation to the patient.

[0055] In treatment as herein described, method and purposes, gamete maturation hormone and comprise α2,3- and α2, the administration of 6-sialylated recombinant human FSH starts on the first day of treatment and can continue two to twenty days, for example, continue 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19 or 20 days. The administration of gamete maturation hormone and recombinant FSH starts from the first day of treatment and can continue four to twenty days, for example, seven to 13 days, for example, nine to 13 days, for example, 10 to 13 days, for example, 10 to 11 days. The dosage of recombinant FSH is the same every day, as determined by the established algorithm based on body weight and serum AMH level, as described below. However, it can be measured according to the patient's serum estradiol (E 2 ) level, adjust the daily dose of gametogenesis hormone from the stimulated mid-follicle stage.

[0056] It should be understood that the stimulated follicular metaphase usually occurs after 4 to 6 days of stimulation, for example, on the 5th, 6th or 7th day of stimulation. 2 ) levels can be measured in the middle of the stimulated follicle phase (e.g., day 5, 6, or 7). 2 ) level, the daily dose of gametogenic hormone should be adjusted from the next day. 2) levels are measured on day 5, 6, or 7 of stimulation; from day 6, 7, or 8 of stimulation onwards, the daily dose of gametogenic hormone can be adjusted (increased or decreased) or maintained.

[0057] As used herein, "equivalent to" in relation to administration means a dose having the same pharmaceutical effect as the dose described in the claims or herein. For example, a dose of or equivalent to 12 μg per day may be a dose of 12 μg per day, or may be a pharmaceutically equivalent dose, such as a dose of 36 μg every 3 days. It should be understood that this applies to any dose described herein.

[0058] treat

[0059] In the exploratory studies described below, the inventors demonstrated the effectiveness of a mixed regimen of gametogenic maturation hormone (hMG, such as HP-hMG) and recombinant human follicle-stimulating hormone (rFSH) (e.g., follitropin delta) personalized based on AMH and weight in the treatment of infertility in patients ≥35 years of age.

[0060] The results of the study showed that the number of good-quality, usable blastocysts obtained on embryo culture day 5 or 6 could be statistically significantly increased using this combined regimen (without compromising safety) compared with cycles using follitropin delta as monotherapy. The subgroups of patients aged 35 to 36 years and 37 to 40 years seemed to benefit most from the use of this combined regimen. For example, the mean (corrected) number of good-quality blastocysts on days 5 to 6 after fertilization was 4.03 ± 0.72 and 4.24 ± 0.62 in the 35.0-36.9 and 37.0-40.0 age groups, respectively, compared with 2.0 ± 2.2 in all age groups using follitropin delta as monotherapy. The incidence of OHSS of any grade was 9.3% (7.4% in the elderly group, 35.0-36.9 age group, and 37.0-40.0 age group) compared with 2.6% in the corresponding groups using follitropin delta as monotherapy. No cases of moderate or severe OHSS were observed in this study, whereas OHSS cases were observed in 1.4% of patients using follitropin delta as monotherapy. The percentage of patients who did not require HP-hMG dose adjustments was 70.83% and 54.84% for the 35.0-36.9 and 37.0-40.0 age groups, respectively. As this study was exploratory and adjustments to the medication regimen were anticipated, it is noteworthy that this percentage of these patients did not require changes in HP-hMG doses.

[0061] In a first aspect, a product is provided, comprising gamete maturation hormone (hMG) and recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation; wherein the product is used in the treatment of infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the product will be administered as follows: the dose of recombinant human FSH including α2,3- and α2,6-sialylation is or is equivalent to 11-13 μg (e.g., 12 μg) per day, and the dose of gamete maturation hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day. The dose of hMG can be a dose of gamete maturation hormone equivalent to 75 IU to 225 IU HP-hMG per day.

[0062] Use may include determining a patient's serum AMH level (e.g., using an automated The invention relates to a method of treating a patient with a serum AMH level of less than 15 pmol / L and a step of administering a dose of recombinant human FSH comprising α2,3- and α2,6-sialylated recombinant human FSH and a dose of a gametogenic maturation hormone.

[0063] The patient may be aged 35 to 40 years or >40 years. Use may include the step of determining the patient's age, and the step of administering gamete maturation hormone (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated to a patient aged 35-40 years (e.g., 35-36 years). Use may include the step of determining the patient's age, and the step of administering gamete maturation hormone (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated to a patient aged >40 years.

[0064] The use may further include determining the patient's serum estradiol (E 2 ) level. The patient's serum estradiol (E 2 ) levels in order to monitor the response to stimulation and subsequently adjust the daily dose of gametogenic hormone and / or select a triggering drug for final follicle maturation, as described in more detail below. 2 ) levels can be determined by methods known in the art.

[0065] The product can be administered from day 1 of stimulation to at least day 5, 6 or 7 of stimulation. From day 6, 7 or 8 of stimulation, the product can be administered at a daily dose of gametogenic hormone (maintaining the rFSH dose at the (initial) day 1 dose) based on the patient's serum estradiol (E 2 ) levels to maintain, increase or decrease. Thus, use may include determining the patient's serum estradiol (E 2 ) level, and the step of administering to the patient a daily dose of gametogen maturation hormone (human menopausal gonadotropin or hMG) starting from the 6th, 7th or 8th day of stimulation, wherein the daily dose of gametogen maturation hormone is maintained, increased or decreased relative to the starting dose.

[0066] From day 6, 7 or 8 of stimulation, (i) on day 5, 6 or 7 of stimulation, estradiol (E 2 ) level> 3000 pmol / L, the daily dose of gametogenic hormone can be reduced by up to 75 IU (relative to the starting dose) (e.g., by 37.5 IU, by 75 IU, or by any amount between 37.5 IU and 75 IU); or (ii) on the 5th, 6th, or 7th day of stimulation, estradiol (E 2 ) level> 3000pmol / L, the daily dose of gametogenic hormone can be reduced to zero. Therefore, use may include determining the patient's serum estradiol (E 2 ) level, and the step of administering a daily dose of gametogenic hormone (hMG), (i) starting from the 6th, 7th or 8th day of stimulation, and (ii) administering a daily dose of estradiol (E ) on the 5th, 6th or 7th day of stimulation. 2 ) level> 3000 pmol / L, the daily dose of gametogenic hormone (relative to the starting dose) is reduced by up to 75 IU (e.g., by 37.5 IU, by 75 IU, or by any amount between 37.5 IU and 75 IU); or (ii) starting on day 6, 7, or 8 of stimulation, on day 5, 6, or 7 of stimulation, estradiol (E 2 ) levels >3000 pmol / L, the daily dose of gametogenetic hormone was reduced to zero.

[0067] From day 6, 7 or 8 of stimulation, (i) on day 5, 6 or 7 of stimulation, estradiol (E 2 ) levels of 750-999 pmol / L, the daily dose of gametogenic hormone may be increased (relative to the starting dose) by up to 150 IU (e.g., by 75 IU, by 150 IU, or by any amount between 75 IU and 150 IU), or (ii) on days 5, 6, or 7 of stimulation with estradiol (E 2) level <750pmol / L, the daily dose of gametogenic hormone can be increased to a dose of 225IU. Thus, use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation, to the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level of 750-999 pmol / L, wherein the daily dose of gametogenic hormone (hMG) is increased by up to 150 IU (e.g., by 75 IU, by 150 IU, or by any amount between 75 IU and 150 IU) to a patient whose serum estradiol (E ) level is 750-999 pmol / L. Thus, the use may include determining the patient's serum estradiol (E ) level on day 5, 6, or 7. 2 ) level, and from the 6th, 7th or 8th day of stimulation to the 5th, 6th or 7th day of stimulation. 2 ) levels <750 pmol / L, the daily dose of gametogenin (hMG) was increased to 225 IU.

[0068] From the 6th, 7th or 8th day of stimulation, estradiol (E 2 ) level between 1000 and 3000 pmol / L, the daily dose of gametogenic hormone (at the starting dose) can be maintained. Thus, use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation to the 5th, 6th or 7th day of stimulation. 2 ) level between 1000 and 3000 pmol / L, wherein the step of administering a dose of a gametogenic hormone of 37.5 IU to 225 IU HP-hMG per day is or is equivalent to 37.5 IU to 225 IU HP-hMG per day. Thus, the use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation to the 5th, 6th or 7th day of stimulation. 2 ) levels between 1000 and 3000 pmol / L, a step of administering a gametogenic hormone at a dose of or equivalent to 75 IU to 225 IU HP-hMG per day.

[0069] The use may include the additional step of triggering ovulation by administering hCG to a patient who, after stimulation, has ≥ 3 follicles each ≥ 17 mm in diameter and estradiol (E 2) level <10,000 pmol / L; or: administration of a GnRH agonist to a patient who has ≥3 follicles with a diameter of ≥17 mm and estradiol (E 2 ) level between 10,000 pmol / L and 15,000 pmol / L; or administration of a GnRH agonist to a patient who has ≥20 follicles and each follicle is ≥12 mm in diameter after stimulation and / or estradiol (E 2 ) level ≥ 15,000 pmol / mL or ≥ 20,000 pmol / mL. The dose of hCG to be administered to the patient may be 5,000 IU to 10,000 IU or 150 to 500 μg recombinant hCG, such as 250 μg recombinant hCG. Use may include an additional step of administering a GnRH antagonist starting on day 6 of stimulation.

[0070] Use may further include one or more or all of the following: extracting (e.g., harvesting) one or more oocytes; fertilizing the one or more oocytes (e.g., artificial insemination); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) blastocysts.

[0071] The gametogenic hormone and rFSH including α2,3- and α2,6-sialylated are administered separately, for example, rFSH including α2,3- and α2,6-sialylated is used for administration in the morning, and the gametogenic hormone is used for administration in the afternoon or evening. Alternatively, the gametogenic hormone and rFSH including α2,3- and α2,6-sialylated are administered together.

[0072] In some aspects, gamete maturation hormone is highly purified gamete maturation hormone (HP-hMG). In some aspects, rFSH is wherein 50% to 95% of total sialylation is α2,3-sialylation and wherein 5%-50% of total sialylation is α2,6-sialylated rFSH. In some aspects, rFSH is wherein 80% to 90% of total sialylation is α2,3-sialylation and wherein 10%-20% of total sialylation is α2,6-sialylated rFSH (e.g., follitropin δ, available from Ferring Pharmaceuticals (Ferring BV)).

[0073] In some aspects, the initial daily dose of gametocyte maturation hormone (hMG) is: 75 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is <12 μg; 150 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is 12 μg and the patient weighs <100 kg; and 225 IU, when the daily dose of recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylated is 12 μg and the patient weighs ≥100 kg.

[0074] Use may include an additional step of assessing follicular growth by ultrasound examination, for example on days 9, 10, 11, 12, 13, 14, etc. of stimulation.

[0075] In a second aspect, a product is provided, the product comprising a gamete maturation hormone and a recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation; wherein the product is used in the treatment of infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35 to 36 years) with a serum AMH level of ≥15 pmol / L (e.g., 15-35 pmol / L) before treatment / stimulation; and wherein the product will be administered as follows: a dose of recombinant human FSH comprising α2,3- and α2,6-sialylation is or is equivalent to 0.09-0.19 μg per kg of patient body weight per day, and a dose of a gamete maturation hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day. The dose of hMG can be a gamete maturation hormone at a dose of or is equivalent to 75 IU to 225 IU HP-hMG per day.

[0076] Use may include determining a patient's serum AMH level (e.g., using an automated AMH, or similar method), and a step of administering a dose of α2,3- and α2,6-sialylated recombinant human FSH and a dose of gametogenin to a patient with a serum AMH level ≥15 pmol / L (e.g., 15-35 pmol / L).

[0077] The patient may be aged 35 to 40 years or >40 years. Use may include the step of determining the patient's age, and the step of administering gamete maturation hormone (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated to a patient aged 35-40 years (e.g., 35-36 years). Use may include the step of determining the patient's age, and the step of administering gamete maturation hormone (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated to a patient aged >40 years.

[0078] The use may further include determining the patient's serum estradiol (E 2 ) level. The patient's serum estradiol (E 2 ) levels in order to monitor the response to stimulation and subsequently adjust the daily dose of gametogenic hormone and / or select a triggering drug for final follicle maturation, as described in more detail below. 2 ) levels can be determined by methods known in the art.

[0079] The product can be administered from day 1 of stimulation to at least day 5, 6 or 7 of stimulation. From day 6, 7 or 8 of stimulation, the product can be administered at a daily dose of gametogenic hormone (maintaining the rFSH dose at the (initial) day 1 dose) based on the patient's serum estradiol (E 2 ) levels to maintain, increase or decrease. Thus, use may include determining the patient's serum estradiol (E 2 ) level, and the step of administering to the patient a daily dose of gametogen maturation hormone (human menopausal gonadotropin or hMG) starting from the 6th, 7th or 8th day of stimulation, wherein the daily dose of gametogen maturation hormone is maintained, increased or decreased relative to the starting dose.

[0080] From day 6, 7 or 8 of stimulation, (i) on day 5, 6 or 7 of stimulation, estradiol (E 2 ) level> 3000 pmol / L, the daily dose of gametogenic hormone can be reduced by up to 75 IU (relative to the starting dose) (e.g., by 37.5 IU, by 75 IU, or by any amount between 37.5 IU and 75 IU); or (ii) on the 5th, 6th, or 7th day of stimulation, estradiol (E 2 ) level> 3000pmol / L, the daily dose of gametogenic hormone can be reduced to zero. Therefore, use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation, to the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level> 3000pmol / L, wherein the daily dose of gametogenic hormone (hMG) is (i) reduced by up to 75 IU (e.g., by 37.5 IU, by 75 IU, or by any amount between 37.5 IU and 75 IU) (relative to the starting dose); or (ii) starting on day 6, 7, or 8 of stimulation, and increasing the daily dose of estradiol (E ) by 1.5% on day 5, 6, or 7 of stimulation. 2) levels >3000 pmol / L, the daily dose of gametogenetic hormone can be reduced to zero.

[0081] From day 6, 7 or 8 of stimulation, (i) on day 5, 6 or 7 of stimulation, estradiol (E 2 ) levels of 750-999 pmol / L, the daily dose of gametogenic hormone may be increased (relative to the starting dose) by up to 150 IU (e.g., by 75 IU, by 150 IU, or by any amount between 75 IU and 150 IU), or (ii) on days 5, 6, or 7 of stimulation with estradiol (E 2 ) level <750pmol / L, the daily dose of gametogenic hormone can be increased to a dose of 225IU. Thus, use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation, to the 5th, 6th or 7th day of stimulation, estradiol (E 2 ) level of 750-999 pmol / L, wherein the daily dose of gametogenic hormone (hMG) is increased by up to 150 IU (e.g., by 75 IU, by 150 IU, or by any amount between 75 IU and 150 IU) (relative to the starting dose). Thus, use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation to the 5th, 6th or 7th day of stimulation. 2 ) levels <750 pmol / L, the daily dose of gametogenin (hMG) was increased to 225 IU.

[0082] From the 6th, 7th or 8th day of stimulation, estradiol (E 2 ) level between 1000 and 3000 pmol / L, the daily dose of gametogenic hormone (at the starting dose) can be maintained. Thus, use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation to the 5th, 6th or 7th day of stimulation. 2 ) level between 1000 and 3000 pmol / L, wherein the step of administering a dose of a gametogenic hormone of 37.5 IU to 225 IU HP-hMG per day is or is equivalent to 37.5 IU to 225 IU HP-hMG per day. Thus, the use may include determining the patient's serum estradiol (E 2 ) level, and from the 6th, 7th or 8th day of stimulation to the 5th, 6th or 7th day of stimulation.2 ) levels between 1000 and 3000 pmol / L, a step of administering a gametogenic hormone at a dose of or equivalent to 75 IU to 225 IU HP-hMG per day.

[0083] The use may include the additional step of triggering ovulation by administering hCG to a patient who, after stimulation, has ≥ 3 follicles each ≥ 17 mm in diameter and estradiol (E 2 ) level <10,000 pmol / L; or GnRH agonists are administered to patients who have ≥3 follicles with a diameter of ≥17 mm each and estradiol (E 2 ) level between 10,000 pmol / L and 15,000 pmol / L; or administration of a GnRH agonist to a patient who has ≥20 follicles and each follicle is ≥12 mm in diameter after stimulation and / or estradiol (E 2 ) level ≥ 15,000 pmol / mL or ≥ 20,000 pmol / mL. The dose of hCG to be administered to the patient may be 5,000 IU to 10,000 IU or 150 to 500 μg recombinant hCG, such as 250 μg recombinant hCG. Use may include an additional step of administering a GnRH antagonist starting on day 6 of stimulation.

[0084] Use may further include one or more or all of the following: extracting (e.g., harvesting) one or more oocytes; fertilizing the one or more oocytes (e.g., artificial insemination); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) blastocysts.

[0085] The gametogenic hormone and rFSH including α2,3- and α2,6-sialylated are administered separately, for example, rFSH including α2,3- and α2,6-sialylated is used for administration in the morning, and the gametogenic hormone is used for administration in the afternoon or evening. Alternatively, the gametogenic hormone and rFSH including α2,3- and α2,6-sialylated are administered together.

[0086] In some aspects, gamete maturation hormone is highly purified gamete maturation hormone (HP-hMG). In some aspects, rFSH is wherein 50% to 95% of total sialylation is α2,3-sialylation and wherein 5%-50% of total sialylation is α2,6-sialylated rFSH. In some aspects, rFSH is wherein 80% to 90% of total sialylation is α2,3-sialylation and wherein 10%-20% of total sialylation is α2,6-sialylated rFSH (e.g., follitropin δ, available from Ferring Pharmaceuticals (Ferring BV)).

[0087] In some aspects, the initial dose of gametocyte maturation hormone (hMG) is: 75 IU, when the dose of α2,3- and α2,6-sialylated recombinant human follicle stimulating hormone (rFSH) is <12 μg; 150 IU, when the dose of α2,3- and α2,6-sialylated recombinant human follicle stimulating hormone (rFSH) is 12 μg and the patient weighs <100 kg; and 225 IU, when the dose of α2,3- and α2,6-sialylated recombinant human follicle stimulating hormone (rFSH) is 12 μg and the patient weighs ≥100 kg.

[0088] Use may include an additional step of assessing follicular growth by ultrasound examination, for example on days 9, 10, 11, 12, 13, 14, etc. of stimulation.

[0089] On the other hand, a method for treating infertility in a patient of ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) and a serum AMH level of <15 pmol / L before treatment is provided, the method comprising: identifying a patient of ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) and a serum AMH level of <15 pmol / L before treatment; and administering to the patient human menopausal gonadotropin (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated, wherein the rFSH is administered at a dose of 11-13 μg (e.g., 12 μg) rFSH per day or a dose equivalent thereto, and the hMG is administered at a dose of 37.5 IU to 225 IU highly purified hMG (HP-hMG) per day or a dose equivalent thereto. The dose of hMG may be a gamete maturation hormone at a dose of or equivalent to 75 IU to 225 IU HP-hMG per day.

[0090] On the other hand, a method for treating infertility in a patient ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) and having a serum AMH level of <15 pmol / L before treatment is provided, the method comprising: identifying a patient ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) and having a serum AMH level of ≥15 pmol / L (e.g., 15-35 pmol / L) before treatment; and administering to the patient a product comprising human menopausal gonadotropin (hMG) and recombinant human follicle-stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation, wherein the rFSH is administered at a dose of 0.09-0.19 μg of rFSH per kg of patient body weight per day, or a dose equivalent thereto, and the hMG is administered at a dose of 37.5 IU to 225 IU of highly purified hMG (HP-hMG) per day, or a dose equivalent thereto. The dose of hMG may be a dose of gametogen at or equivalent to 75 IU to 225 IU HP-hMG per day.

[0091] It will be appreciated that the methods of treatment described above may be used in accordance with any aspect of the invention disclosed herein.

[0092] On the other hand, a pharmaceutical composition comprising gametogenic hormone (hMG) is provided for use in treating infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the pharmaceutical composition is to be administered as follows: the dose of gametogenic hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day, and the dose of recombinant human FSH (rFSH) including α2,3- and α2,6-sialylated is or is equivalent to 11-13 μg (e.g., 12 μg) per day.

[0093] On the other hand, a pharmaceutical composition comprising α2,3- and α2,6-sialylated recombinant human follicle-stimulating hormone (rFSH) is provided for use in treating infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the pharmaceutical composition is to be administered as follows: a dose of α2,3- and α2,6-sialylated recombinant human FSH is or is equivalent to 11-13 μg (e.g., 12 μg) per day, and a dose of gametogenetic hormone (hMG) is or is equivalent to 37.5 IU to 225 IU HP-hMG per day.

[0094] On the other hand, a pharmaceutical composition comprising gametogenic hormone (hMG) is provided for use in treating infertility in patients ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) whose serum AMH level before treatment / stimulation is ≥15 pmol / L (e.g., 15-35 pmol / L); wherein the pharmaceutical composition is to be administered as follows: the dose of gametogenic hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day, and the dose of recombinant human FSH (rFSH) including α2,3- and α2,6-sialylated is or is equivalent to 0.09-0.19 μg per kg of patient body weight per day.

[0095] On the other hand, a pharmaceutical composition comprising α2,3- and α2,6-sialylated recombinant human follicle stimulating hormone (rFSH) is provided for use in treating infertility in patients ≥ 35 years old (e.g. 35 to 40 years old, e.g. 35-36 years old) whose serum AMH level before treatment / stimulation is ≥ 15 pmol / L (e.g. 15-35 pmol / L); wherein the pharmaceutical composition is to be administered as follows: a dose of α2,3- and α2,6-sialylated recombinant human FSH is or is equivalent to 0.09-0.19 μg per kg of patient body weight per day, and a dose of gametogenetic hormone (hMG) is or is equivalent to 37.5 IU to 225 IU HP-hMG per day.

[0096] It will be appreciated that the pharmaceutical compositions described above represent product ingredients according to further aspects of the invention and may be used in accordance with any aspect of the invention disclosed herein.

[0097] Combination of gamete maturation hormone, recombinant FSH and rFSH

[0098] The methods and products described herein use recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation. FSH comprises an α subunit of 92 amino acids (also a common subunit of other glycoprotein hormones LH and chorionic gonadotropin (CG)), and a β subunit of 111 amino acids unique to FSH (which confers the biological specificity of the hormone) (Pierce and Parsons, 1981). Each subunit is post-translationally modified by the addition of complex carbohydrate residues. Both subunits carry 2 N-linked glycan attachment sites, the α subunit at amino acids 52 and 78 and the β subunit at amino acid residues 7 and 24 (Rathnam and Saxena, 1975, Saxena and Rathnam, 1976). Thus, FSH is glycosylated to about 30% by mass (Dias and Van Roey. 2001. Fox et al. 2001).

[0099] The glycosylation of rFSH products reflects the scope of glycosyltransferases present in host cell lines. Commercially available rFSH products derived from engineered Chinese hamster ovary cells (CHO cells) have more limited polysaccharide modification scopes than those found in natural products. The example of polysaccharide heterogeneity found in CHO cell-derived rFSH includes the lack of bisected glucosamine and the reduction of the content of core fucosylation and acetyllactosamine extension (Hard et al., 1990). In addition, CHO cells can only add sialic acid (Kagawa et al., 1988, Takeuchi et al., 1988, Svensson et al., 1990) at α2,3 bonds; therefore, CHO cell-derived rFSH only includes sialic acid connected by α2,3-, and does not include sialic acid connected by α2,6-. Thus, CHO cell-derived rFSH differs from naturally occurring FSH (eg, human pituitary / serum / urinary FSH), which contains glycans with a mixture of α2,3 and α2,6-linked sialic acids (ie, α2,3- and α2,6-sialylation), with the former predominating.

[0100] The applicant has developed human cell line derived rFSH which is the subject of international patent application number PCT / GB2009 / 000978 published as WO 2009 / 127826A and which was also approved by the European Commission as (Follitropin delta, also known as FE 999049). This recombinant FSH with a mixture of α2,3 and α2,6-linked sialic acids (i.e., α2,3- and α2,6-sialylated) is prepared by engineering a human cell line to express rFSH and α2,3-sialyltransferase. The amino acid sequence of the human cell line-derived recombinant FSH, which is the subject of International Patent Application No. PCT / GB2009 / 000978 published as WO 2009 / 127826A (e.g., follitropin delta / FE 999049), is the native human FSH sequence, but the product has a different glycosylation pattern. The expressed product is highly acidic and carries a mixture of α2,3- and α2,6-linked sialic acids (i.e., α2,3- and α2,6-sialylated); the latter is provided by endogenous sialyltransferase activity. It was found that the type of sialic acid linkage α2,3- or α2,6- has a significant effect on the biological clearance of FSH. Therefore, compared with CHO cell-derived recombinant products with only α2,3-linked sialic acid (Kagawa et al., 1988, Takeuchi et al., 1988, Svensson et al., 1990) and with reduced sialic acid content (Ulloa-Aguirre et al. 1995., Andersen et al. 2004), (e.g., follitropin delta / FE 999049) may be more biologically appropriate.

[0101] Thus, the recombinant FSH including α2,3- and α2,6-sialylated FSH used in accordance with the methods and products described herein can be grown in human cell lines (e.g. Recombinant FSH can be produced or expressed in Cell lines, Derived cell lines or modified Produced or expressed in cell lines. The recombinant FSH produced or expressed in the cell line will include some α2,6-connected sialic acids (α2,6 sialylation) provided by the endogenous sialyltransferase activity (of the cell line), and will include some α2,3-connected sialic acids (α2,3 sialylation) provided by the endogenous sialyltransferase activity. The cell line can be modified using α2,3-sialyltransferase. The cell line can be modified using α2,6-sialyltransferase. Alternatively or additionally, the recombinant FSH may include α2,6-connected sialic acids (α2,6 sialylation) provided by the endogenous sialyltransferase activity (of the cell line). In this article, the term "human-derived recombinant FSH" means recombinant FSH produced or expressed in a human cell line (e.g., recombinant FSH prepared by engineering human cell line).

[0102] The recombinant FSH used in the methods and products described herein may include α2,3- and α2,6-sialylation. The recombinant FSH used according to the present invention may have 1% to 99% of total sialylation as α2,3-sialylation. The recombinant FSH used according to the present invention may have 1% to 99% of total sialylation as α2,6-sialylation. The recombinant FSH may have 1% to 50% of total sialylation as α2,6-sialylation, and 50% to 99% of total sialylation as 2,3-sialylation. For example, 80% to 95% (e.g., 80% to 90%, e.g., 82% to 89%, e.g., 85% to 89%) of the total sialylation may be α2,3-sialylation. For example, 5% to 20%, e.g., 10% to 20%, e.g., 11% to 18%, e.g., 11% to 15% of the total sialylation may be α2,6-sialylation. In an example, the recombinant FSH has 5% to 20% of the total sialylation as α2,6-sialylation, and 80% to 95% of the total sialylation as 2,3-sialylation. In another example, the recombinant FSH has 50% to 80% of the total sialylation as α2,6-sialylation, and 20% to 50% of the total sialylation as 2,3-sialylation.

[0103] In this text, "sialylation" means the amount of sialic acid residues present on the recombinant FSH carbohydrate structure. Consistent with the usage in the art, α2,3-sialylation means sialylation at the 2,3 position and α2,6-sialylation means sialylation at the 2,6 position. Thus, "the % in total sialylation can be α2,3-sialylation" refers to the % of the total number of sialic acid residues present in FSH (or hCG) sialylated at the 2,3 position. The term "the % in total sialylation is α2,6-sialylation" refers to the % of the total number of sialic acid residues present in FSH (or hCG) sialylated at the 2,6 position.

[0104] In all respects, rFSH can exist as a single isoform or a mixture of isoforms.

[0105] Recombinant FSH and hMG can be formulated into compositions well-known for any route of drug administration, e.g., oral, rectal, parenteral, transdermal (e.g., patch technology), intravenous, intramuscular, subcutaneous (e.g., for subcutaneous injection), intracisternal, intravaginal, intraperitoneal, topical (powder, ointment or drops) or as an oral or nasal spray. Typical compositions contain a pharmaceutically acceptable carrier, such as an aqueous solution, non-toxic excipients (including salts and preservatives, buffers, etc.), as described in Remington’s Pharmaceutical Sciences, Fifteenth Edition (Matt Publishing Company, 1975), pages 1405 to 1412 and 1461 - 87, and the Fourteenth Edition of the national formulary XIV (American Pharmaceutical Association, 1975), etc. For example, recombinant FSH, the composition or the pharmaceutical composition can be formulated for injection, such as for subcutaneous injection.

[0106] Examples of suitable aqueous and non-aqueous pharmaceutical carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters (such as ethyl oleate).

[0107] The composition may also include additives such as, but not limited to, preservatives, wetting agents, emulsifiers, surfactants, and dispersants. Antibacterial and antifungal agents may be included to prevent microbial growth, and include, for example, meta-cresol, benzyl alcohol, parabens, chlorobutanol, phenol, sorbic acid, and the like. If a preservative is included, benzyl alcohol, phenol, and / or meta-cresol are preferred; however, the preservative is by no means limited to these examples. In addition, isotonic agents such as sugars, sodium chloride, amino acids, and the like may need to be included.

[0108] For example, the composition or drug may comprise recombinant FSH and one or more of polysorbate 20, L-methionine, phenol and arginine hydrochloride. Such a composition may be formulated for injection, such as for subcutaneous injection. For example, the rFSH composition or drug may be Formulation (Follitropin delta with excipients phenol, polysorbate 20, L-methionine, sodium sulfate decahydrate, sodium phosphate dibasic dodecahydrate, phosphoric acid [concentrated, for pH adjustment], sodium hydroxide [for pH adjustment] and water for injection).

[0109] Injectable formulations can be sterilized, for example, by filtration through a bacterial barrier filter, or by adding sterilizing agents in the form of sterile solid compositions (which can be dissolved or dispersed in sterile water or other sterile injectable media before use). Injectable formulations can be provided in any suitable container (e.g., vials, prefilled syringes, injection boxes, etc.).

[0110] Recombinant FSH, compositions or medicine can be formulated for single use or for multiple use (multiple doses). If recombinant FSH, compositions or medicine are formulated for multiple use, one or more preservatives are typically included. If preservatives are included, benzyl alcohol, phenol or meta-cresol are preferred; however, preservatives are by no means limited to these examples. The single use or multiple use compositions or medicines prepared can further include amino acids or amino acid combinations. Typically, the amino acid is arginine, for example, is added as arginine or more typically arginine hydrochloride.

[0111] The recombinant FSH, composition or medicament may be included in a container, such as a vial, a prefilled cartridge (eg, for single administration or multiple uses), or an injection device (eg, a "pen," for multiple dose administration, for example).

[0112] The recombinant FSH, composition or pharmaceutical composition may be a formulation (eg, an injectable formulation) comprising rFSH.

[0113] Recombinant FSH, compositions or medicines can be provided with any suitable packaging.For example, compositions or medicines can include multiple containers (for example, pre-filled syringes or vials) containing FSH.Syringes or vials can be packaged in blister packs or keep sterile by other means.Any compositions or medicines can optionally include instructions for use of FSH preparations.

[0114] The pH and the exact concentration of the various components of the pharmaceutical composition are adjusted according to conventional practice in the art. See GOODMAN and GILMAN's THE PHARMACOLOGICAL BASIS FOR THERAPEUTICES, the 7th edition. In a typical embodiment, recombinant FSH, compositions or drugs are provided as parenteral compositions. The general method for preparing parenteral formulations is known in the art and is described in REMINGTON; THE SCIENCE AND PRACTICE OF PHARMACY, ibid., pp. 780-820. The parenteral composition can be provided in liquid formulation form or as a solid, which will be mixed with a sterile injectable medium just before administration. Parenteral compositions can be provided in dosage unit form to be easy to use and to achieve dosage uniformity.

[0115] In a further aspect, there is provided the use of recombinant follicle stimulating hormone (FSH) in the manufacture of a medicament for use as described herein.

[0116] Further aspects are demonstrated in the following examples, which are not limiting in any respect.

[0117] The gametogenic hormone (e.g., human menopausal gonadotropin (hMG)) used in the methods and products described herein can be a highly purified gametogenic hormone. As used herein, the term "highly purified gametogenic hormone" includes the gametogenic hormone available from Ferring Pharmaceuticals under the trade name HP-hMG, which contains follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) driven luteinizing hormone (LH) activity. In some examples, the hMG used in the methods and products described herein is HP-hMG (e.g., In some examples, the hMG used in the methods and products described herein is HP-hMG products, which are usually provided in the form of lyophilized powder or granules, are mixed with a sterile diluent (eg, 0.9% sodium chloride for injection) before use. It is a powder and solvent solution for injection. In addition to hMG, the ingredients also include lactose, polysorbate 20, hydrochloric acid, sodium chloride, sodium hydroxide and water for injection.

[0118] Examples

[0119] The following example uses (Follitropin delta) (which was engineered by the methods disclosed in WO 2013 / 020996 and WO 2009 / 127826A recombinant FSH expressed in cell lines) and (It is a highly purified gametogenic hormone (HP-hMG) containing follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) driven luteinizing hormone (LH) activity).

[0120] and The marketing authorisation holder for is Ferring Pharmaceuticals A / S, Kay Fiskers Plads 11, 2300 Copenhagen, Denmark, and In the United Kingdom, it is available from Ferring Pharmaceuticals, Drayton Hall, Church Road, West Drayton, UB7 7PS, UK.

[0121] The active substance in is follitropin delta (FE999049). is highly sialylated and includes α2,3- and α2,6-sialylation, with about 85% to 90% of the total sialylation being α2,3-sialylation and about 10% to 15% of the total sialylation being α2,6-sialylation.

[0122] It is a transparent colorless solution for injection (injection). One milliliter of solution contains 33.3 micrograms of follitropin delta in each milliliter of solution. The other ingredients are phenol, polysorbate 20, L-methionine, sodium sulfate decahydrate, disodium hydrogen phosphate dodecahydrate, concentrated phosphoric acid, sodium hydroxide and water for injection.

[0123] The active ingredient in Glucocorticoids is human menopausal gonadotropin (HMG).

[0124] It is a powder and solvent solution for injection. The other ingredients are lactose, polysorbate 20, hydrochloric acid, sodium chloride, sodium hydroxide and water for injection. (For example, 75IU injection, 1200 IU powder and solution for injection) is available in the UK from Ferring Pharmaceuticals, Drayton Hall, Church Road, West Drayton, UB7 7PS, UK.

[0125] Example 1: Menopur and Rekovelle Combination Study (MARCS): An exploratory study evaluating the effects of individualized doses of follitropin delta and highly purified human menopausal gonadotropin (HP-hMG) on controlled ovarian stimulation

[0126] introduce

[0127] The MARCS study was designed to compare the efficacy of individualized versus conventional ovarian stimulation for in vitro fertilization with the Evidence-based Stimulation Trial with Human Recombinant Follicle-Stimulating Hormone in Europe and Rest of World 1 (ESTHER-1) trial (Nyboe-Andersen A, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC; ESTHER-1 study group). To evaluate the mean number of good-quality blastocysts obtained on days 5 and 6 and the proportion of women developing ovarian hyperstimulation syndrome (OHSS) after treatment with an individualized dosing regimen of follitropin delta and highly purified human menopausal gonadotropin (HP-hMG) compared with treatment with individualized doses of follitropin delta as monotherapy.

[0128] method

[0129] This was a multicenter, open-label, single-cohort study with external (synthetic) controls that evaluated the efficacy and safety of personalized doses of follitropin delta in combination with HP-hMG (hybrid regimen). Patients were enrolled at four study sites in Canada. The study protocol was approved by local regulatory authorities and independent ethics committees. The study was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and local regulatory requirements. All participants provided written informed consent before undergoing any study-related procedures.

[0130] Study participants

[0131] Women included in the study were aged 18-40 years, diagnosed with infertility (including stage I / II endometriosis or tubal factor), and undergoing their first IVF / intracytoplasmic sperm injection (ICSI) cycle. Additional inclusion criteria were regular menstrual cycles of 24-35 days, two ovaries, fertilization with ejaculated sperm (fresh or frozen), and early follicular phase FSH serum concentration <10 IU / L. The main exclusion criteria were stage III / IV endometriosis, high risk of OHSS (AMH>35 pmol / L), history of recurrent miscarriage (defined as ≥3 consecutive miscarriages), and use of hormone therapy (except thyroid medication) during the last menstrual cycle before inclusion in the study.

[0132] Study Procedure

[0133] All patients participating in this study received a fixed, personalized daily subcutaneous dose of follitropin delta ( Ferring Pharmaceuticals), the dose was determined by an established algorithm based on body weight and serum AMH levels (Table 1), which is the subject of International Patent Application No. PCT / EP2012 / 065507 published as WO 2013 / 020996. Serum AMH measurements were performed at a central laboratory (CreATe FertilityCentre) using the automated Elecsys AMH immunoassay (Roche) and determined within the last 12 months before the start of ovarian stimulation.

[0134] Table 1: Calculation of daily dose of follitropin delta according to AMH concentration

[0135] AMH concentration (pmol / L) Fixed daily dose of follitropin delta during stimulation <15 12 μg 15-16 0.19 μg / kg 17 0.18 μg / kg 18 0.17 μg / kg 19-20 0.16 μg / kg 21-22 0.15 μg / kg 23-24 0.14 μg / kg 25-27 0.13 μg / kg 28-32 0.12 μg / kg 33-39 0.11 μg / kg ≥40 0.10 μg / kg

[0136] Round the dose to the nearest 0.33 microgram to match the dose scale on the injection pen.

[0137] HP-hMG ( Ferring Pharmaceuticals) was co-administered with follitropin delta at a personalized initial dose to all patients.

[0138] The initial daily dose of HP-hMG is:

[0139] 75 IU when the follitropin delta dose is < 12 μg;

[0140] 150 IU when the daily dose of follitropin delta is 12 μg and the body weight is < 100 kg;

[0141] 225 IU when the daily dose of follitropin delta is 12 μg and the body weight is ≥ 100 kg.

[0142] Gonadotropin therapy was started on day 2 of the menstrual cycle. Gonadotropin-releasing hormone (GnRH) antagonists were started on day 6 of stimulation and continued for the remainder of stimulation. 2 ) levels and vaginal ultrasound to monitor responses to stimulation.

[0143] As this is an exploratory study, adjustments to the drug regimen are anticipated. Any adjustments to the stimulation are limited to HP-hMG and are only permitted starting on day 6 of stimulation. HP-hMG doses may be adjusted based on E 2 Levels were adjusted up or down regardless of follicular development, with a maximum daily dose of 225 IU. HP-hMG dose adjustments were made according to the schedule described in Table 2.

[0144] Table 2: Day 6 Dose Adjustment Chart for HP-hMG

[0145]

[0146] When ≥3 follicles reach a diameter of 17 mm, final follicular maturation is triggered. The choice of triggering drug is based on the serum E 2 Level: If E 2 <10,000 pmol / L, hCG 5,000–10,000 IU; and if E 2 ≥10,000 pmol / L, GnRH agonist 0.2 mg (triptorelin acetate, Decapeptyl; Ferring Pharmaceuticals). In the case of an overreaction, defined as the serum level E on the day of triggering 2If the ovarian hyperplasia reached ≥15,000 pmol / L or ≥20 follicles with ≥12 mm, a freeze-all strategy was adopted. In case of follicular hypoplasia, defined as reaching <3 follicles with ≥17 mm on day 20, the cycle was cancelled.

[0147] Oocyte retrieval was performed 36 ± 2 hours after triggering final follicular maturation. Oocytes were artificially inseminated by IVF or ICSI using sperm from the partner or donor. All embryos were cultured up to day 5 or 6. All fresh embryo transfers were performed on day 5 of culture, and all were single embryo transfers.

[0148] When the remaining blastocysts were graded 3BB or higher according to the Gardner classification, they were cryopreserved for future use. Intramuscular progesterone was prescribed daily for luteal phase support. Adverse events were recorded from the signing of the informed consent until the end of the study (defined as day 6 blastocyst formation). If any adverse event was reported during the study visit, the study team conducted a follow-up telephone communication until the adverse event resolved.

[0149] Study Results

[0150] The primary endpoint of the study was the number of good-quality (>3BB) blastocysts (usable blastocysts) on days 5 and 6. Secondary objectives were ovarian response, embryology, and safety of the protocol. Ovarian response and embryology included the duration of stimulation, the total dose of follitropin delta, the percentage of patients triggered by GnRH agonist, the mean number of mature oocytes obtained, the mean number of embryos on day 3, and the percentage of day 3 embryos that evolved into usable blastocysts on day 5 or day 6 (loss rate). Safety was evaluated by assessing the incidence and severity of early-onset and late-onset moderate-to-severe OHSS, classified according to the Golan system (see Table 3).

[0151] Table 3: OHSS classification

[0152]

[0153]

[0154] result

[0155] The study used a single-cohort, open-label design with an external (synthetic) control as comparator. Patients enrolled in the ESTHER-1 trial received personalized doses of follitropin delta, which was used as a comparator. Table 4 shows the primary and secondary endpoints of the MARCS cohort compared with ESTHER-1, and Table 5 shows the primary and secondary endpoints of the MARCS cohort distributed by age group.

[0156] Table 4: Primary and secondary endpoints by cohort

[0157]

[0158] Note: Unless otherwise stated, the values ​​are mean ± SD or numbers and percentages. CCOO = cumulus ovale; ESTHER-1 = Evidence-Based Stimulation Trial of Human rFSH in Europe and Rest of the World 1; GnRH = gonadotropin-releasing hormone; MARCS = Menopur and Rekovelle Combined Study; MII = mitotic metaphase II.

[0159] a where N is the number of participants considered for each variable, differing in the cases marked with d and e.

[0160] b ESTHER-1(P) group, with personalized follitropin delta dose.

[0161] c Observed / uncorrected estimates.

[0162] d N = 106 patients. Four patients did not obtain usable embryos on day 5 or day 6

[0163] e N = 107 patients. Three patients achieved poor responses leading to cycle cancellation.

[0164] f Although the investigators requested this adjustment, no adjustment was made in the ESTHER-1(P) group per the protocol.

[0165] g The data come from clinical trial reports.

[0166] Table 5: Distribution of primary and secondary endpoints by age group

[0167]

[0168]

[0169]

[0170] Note: Unless otherwise stated, the values ​​are mean ± SD or numbers and percentages. CCOO = cumulus ovale; E2 = estradiol; HP-hMG = highly purified human menopausal gonadotropin; MII = metaphase II; OHSS = ovarian hyperstimulation syndrome.

[0171] aN = number of participants considered for each variable, differing in cases marked with c and d.

[0172] b Least squares means ± standard error of the mean, corrected for antral follicle count and anti-Müllerian hormone level.

[0173] c N = 106 patients. Four patients did not obtain usable embryos on day 5 or day 6

[0174] d N = 107 patients. Three patients achieved poor responses leading to cycle cancellation.

[0175] Tables 4 and 5 show that the number of good-quality, usable blastocysts obtained on embryo culture day 5 or 6 can be statistically significantly increased using the hybrid regimen described herein (without compromising safety) compared to cycles using follitropin delta as monotherapy.

[0176] Subgroups of patients aged 35 to 36 and 37 to 40 years appeared to benefit most from the use of the combined regimen. For example, the mean (corrected) number of high-quality blastocysts on days 5-6 after fertilization was 4.03 ± 0.72 and 4.24 ± 0.62 in the 35.0-36.9 and 37.0-40.0 age groups, respectively, compared to 2.0 ± 2.2 in all age groups using follitropin delta as monotherapy. These results suggest that women older than 35 years of age benefit the most from oocytes extracted according to the combined dosing regimen described herein and evaluated in this study.

[0177] The incidence of OHSS of any grade was 9.3% (7.4% in the elderly group, 35.0-36.9 age group, and 37.0-40.0 age group), compared to 2.6% in the corresponding group using follitropin delta as monotherapy. No cases of moderate or severe OHSS were observed in this study, while OHSS cases were observed in 1.4% of patients using follitropin delta as monotherapy. Therefore, the dosing regimen described herein achieved the intended goal.

[0178] The percentage of patients who did not require HP-hMG dose adjustments for the 35.0-36.9 and 37.0-40.0 age groups was 70.83% and 54.84%, respectively. As this study was exploratory and adjustments to the medication regimen were anticipated, the percentage of these patients who did not require a change in HP-hMG dose is noteworthy.

[0179] in conclusion

[0180] Optimization of IVF ovarian response by using a mixed regimen of both follitropin delta and HP-hMG with individualized dosing resulted in a significant increase in the number of good-quality usable blastocysts on day 5 or 6 with only an increased risk of mild OHSS that did not require medical intervention or hospitalization. The subgroups of patients aged 35 to 36 years and 37 to 40 years appeared to benefit most from the use of this combined regimen.

Claims

1. A product comprising a gametogenic hormone (human menopausal gonadotropin or hMG) and a recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation; wherein the product is used to treat infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the product is to be administered as follows: the dose of the recombinant human FSH comprising α2,3- and α2,6-sialylation is or is equivalent to 11-13 μg (e.g., 12 μg) per day, and the dose of the gametogenic hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG per day.

2. according to the product for use described in claim 1, wherein this use comprises the step of determining the serum AMH level of this patient, and the step of applying this dosage comprising α2,3- and α2,6-sialylated recombinant human FSH and this dosage of gametogenic maturation hormone to the patient whose serum AMH level is <15pmol / L.

3. A product comprising a gametogenic hormone and a recombinant human follicle-stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation; wherein the product is used to treat infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is ≥15 pmol / L; and wherein the product is to be administered as follows: the dose of the recombinant human FSH comprising α2,3- and α2,6-sialylation is or is equivalent to 0.09-0.19 μg per kg of the patient's body weight per day, and the dose of the gametogenic hormone is or is equivalent to 37.5 IU to 225 IU HP-hMG (e.g., 75 IU) per day.

4. A product for use according to claim 3, wherein the use comprises the step of determining the patient's serum AMH level, and administering the dose of recombinant human FSH comprising α2,3- and α2,6-sialylated and the dose of gametogenic hormone to a patient with serum AMH ≥ 15 pmol / L.

5. A product for use according to any preceding claim, wherein the use comprises the additional step of determining the patient's serum estradiol (E2) level during the treatment / stimulation period.

6. A product for use according to any preceding claim, wherein the product is to be administered from day 1 of stimulation to at least day 5, 6 or 7 of stimulation.

7. A product for use according to claim 6, wherein starting from the 6th, 7th or 8th day of stimulation, the product will be administered with a daily dose of gametogenin, and the daily dose of gametogenin is maintained, increased or decreased according to the patient's serum estradiol (E2) level on the 5th, 6th or 7th day of stimulation.

8. A product for use according to claim 7, wherein from the 6th, 7th or 8th day of stimulation, (i) in patients whose estradiol (E2) levels are >3000pmol / L on the 5th, 6th or 7th day of stimulation, the daily dose of the gametogenic hormone (relative to the starting dose) is reduced by up to 75IU (e.g., by 37.5IU, by 75IU or any amount between 37.5IU and 75IU); or (ii) in patients whose estradiol (E2) levels are >3000pmol / L on the 5th, 6th or 7th day of stimulation, the daily dose of the gametogenic hormone is reduced to zero.

9. A product for use according to claim 7, wherein from the 6th, 7th or 8th day of stimulation, (i) in patients whose estradiol (E2) levels are 750-999 pmol / L on the 5th, 6th or 7th day of stimulation, the daily dose of the gametogenic hormone (relative to the starting dose) is increased by up to 150 IU (e.g., by 75 IU, by 150 IU or any amount between 75 IU and 150 IU), or (ii) in patients whose estradiol (E2) levels are <750 pmol / L on the 5th, 6th or 7th day of stimulation, the daily dose of the gametogenic hormone (relative to the starting dose) is increased to a dose of 225 IU.

10. The product for use according to claim 7, wherein the daily dose of the gametogenic hormone is maintained from the 6th, 7th or 8th day of stimulation in patients whose estradiol (E2) levels are between 1000 and 3000 pmol / L on the 5th, 6th or 7th day of stimulation.

11. A product for use according to any preceding claim, wherein the use comprises the additional step of triggering ovulation by administering hCG to a patient who after stimulation has ≥3 follicles each ≥17 mm in diameter and an estradiol (E2) level <10,000 pmol / L; or administering a GnRH agonist to a patient who after stimulation has ≥3 follicles each ≥17 mm in diameter and an estradiol (E2) level between 10,000 pmol / L and 15,000 pmol / L; or administering a GnRH agonist to a patient who after stimulation has ≥20 follicles each ≥12 mm in diameter and / or an estradiol (E2) level ≥15,000 pmol / mL or ≥20,000 pmol / mL.

12. The product for use according to claim 11, wherein the dose of hCG to be administered to the patient is 5,000 IU to 10,000 IU.

13. Product for use according to any one of claims 6 to 12, wherein the use comprises the additional step of administering a GnRH antagonist starting from day 6 of stimulation.

14. A product for use according to any preceding claim, wherein the use further comprises: extracting (e.g., harvesting) one or more oocytes; fertilizing the oocyte or oocytes (e.g., artificial insemination); allowing the fertilized oocytes to develop to the blastocyst stage; and freezing one or more (or all) of the blastocysts.

15. A product for use according to any preceding claim, wherein the gametogenic hormone and the rFSH comprising α2,3- and α2,6-sialylation are administered separately, for example the rFSH comprising α2,3- and α2,6-sialylation is for administration in the morning and the gametogenic hormone is for administration in the afternoon or evening.

16. A product for use according to any preceding claim, wherein the gametogenic hormone is administered together with rFSH comprising α2,3- and α2,6-sialylated rFSH.

17. A product for use according to any preceding claim, wherein the gametogenic hormone is highly purified gametogenic hormone (HP-hMG).

18. A product for use according to any preceding claim, wherein the rFSH is rFSH in which 50% to 95% of the total sialylation is α2,3-sialylation and in which 5%-50% of the total sialylation is α2,6-sialylation.

19. A product for use according to any preceding claim, wherein when the daily dose of the recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation is <12 μg, the daily dose of the gametogenic hormone (human menopausal gonadotropin or hMG) is 75 IU; when the daily dose of the recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation is 12 μg and the patient weighs <100 kg, the daily dose of the gametogenic hormone is 150 IU; and when the daily dose of the recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation is 12 μg and the patient weighs ≥100 kg, the daily dose of the gametogenic hormone is 225 IU.

20. A product for use according to any preceding claim, wherein the use comprises the additional step of assessing follicular growth by ultrasound examination, e.g. on day 9, 10, 11, 12, 13, 14 etc. of stimulation.

21. A method for treating infertility in a patient aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) and having a serum AMH level <15 pmol / L before treatment, the method comprising: Identifying patients ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) with serum AMH levels <15 pmol / L before treatment; and The patient is administered human menopausal gonadotropin (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated forms, wherein the rFSH is administered at a dose of 11-13 μg (e.g., 12 μg) of rFSH per day or a dose equivalent thereto, and the hMG is administered at a dose of 37.5 IU to 225 IU of highly purified hMG (HP-hMG) per day or a dose equivalent thereto.

22. A method for treating infertility in a patient aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) and having a serum AMH level <15 pmol / L before treatment, the method comprising: Identifying patients ≥35 years old (e.g., 35 to 40 years old, e.g., 35-36 years old) with serum AMH ≥15 pmol / L before treatment; and The patient is administered human menopausal gonadotropin (hMG) and recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylated forms, wherein the rFSH is administered at a dose of 0.09-0.19 μg of rFSH per kg of the patient's body weight per day or a dose equivalent thereto, and the hMG is administered at a dose of 37.5 IU to 225 IU of highly purified hMG (HP-hMG) per day or a dose equivalent thereto.

23. A pharmaceutical composition comprising a gametogenic hormone (human menopausal gonadotropin or hMG) for use in the treatment of infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the pharmaceutical composition is to be administered as follows: a dose of the gametogenic hormone of or equivalent to 37.5 IU to 225 IU HP-hMG per day, and a dose of recombinant human FSH (rFSH) comprising α2,3- and α2,6-sialylation of or equivalent to 11-13 μg (e.g., 12 μg) per day.

24. A pharmaceutical composition comprising recombinant human follicle stimulating hormone (rFSH) comprising α2,3- and α2,6-sialylation, for use in treating infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is <15 pmol / L; wherein the pharmaceutical composition is to be administered as follows: the recombinant human FSH comprising α2,3- and α2,6-sialylation is at a dose of or equivalent to 11-13 μg (e.g., 12 μg) per day, and the dose of gamete maturation hormone (human menopausal gonadotropin or hMG) is at or equivalent to 37.5 IU to 225 IU HP-hMG per day.

25. A pharmaceutical composition comprising a gamete maturation hormone (human menopausal gonadotropin or hMG) for use in the treatment of infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH level before treatment / stimulation is ≥15 pmol / L; wherein the pharmaceutical composition is administered as follows: a dose of the gamete maturation hormone of or equivalent to 37.5 IU to 225 IU HP-hMG per day, and a dose of recombinant human FSH (rFSH) comprising α2,3- and α2,6-sialylation of or equivalent to 0.09-0.19 μg per kg of the patient's body weight per day.

26. A pharmaceutical composition comprising recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation, for use in treating infertility in patients aged ≥35 years (e.g., 35 to 40 years, e.g., 35-36 years) whose serum AMH before treatment / stimulation is ≥15 pmol / L; wherein the pharmaceutical composition is administered as follows: the recombinant human FSH including α2,3- and α2,6-sialylation is at a dose of or equivalent to 0.09-0.19 μg per kg of the patient's body weight per day, and the gamete maturation hormone (human menopausal gonadotropin or hMG) is at a dose of or equivalent to 37.5 IU to 225 IU HP-hMG per day.